These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19575395)

  • 1. Electron ionization mass spectrometry of the ryanodine receptor-based Ca(2+)-channel stabilizer S-107 and its implementation into routine doping control.
    Thevis M; Beuck S; Thomas A; Fusshöller G; Sigmund G; Schlörer N; Rodchenkov G; Schäfer M; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Aug; 23(15):2363-70. PubMed ID: 19575395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Thevis M; Kohler M; Thomas A; Schlörer N; Schänzer W
    Rapid Commun Mass Spectrom; 2008 Aug; 22(16):2471-8. PubMed ID: 18634123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for the calstabin-ryanodine receptor complex stabilizers JTV-519 and S-107 in doping control analysis.
    Thevis M; Beuck S; Thomas A; Kohler M; Schlörer N; Vajiala I; Schänzer W
    Drug Test Anal; 2009 Jan; 1(1):32-42. PubMed ID: 20355157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation of urinary metabolites of fluoxymesterone by liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry.
    Pozo OJ; Van Thuyne W; Deventer K; Van Eenoo P; Delbeke FT
    J Mass Spectrom; 2008 Mar; 43(3):394-408. PubMed ID: 18035854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis.
    Thevis M; Kohler M; Maurer J; Schlörer N; Kamber M; Schänzer W
    Rapid Commun Mass Spectrom; 2007; 21(21):3477-86. PubMed ID: 17985352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doping control analysis of trenbolone and related compounds using liquid chromatography-tandem mass spectrometry.
    Thevis M; Guddat S; Schänzer W
    Steroids; 2009 Mar; 74(3):315-21. PubMed ID: 19007801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
    Thevis M; Krug O; Schänzer W
    Rapid Commun Mass Spectrom; 2013 May; 27(9):993-1004. PubMed ID: 23592202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
    Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
    Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
    Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of HPLC/orbitrap mass spectrometry as screening method for doping control.
    Virus ED; Sobolevsky TG; Rodchenkov GM
    J Mass Spectrom; 2008 Jul; 43(7):949-57. PubMed ID: 18563856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of oral antidiabetics and their metabolites in human urine by liquid chromatography/tandem mass spectrometry--a matter for doping control analysis.
    Thevis M; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2005; 19(7):928-36. PubMed ID: 15747323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.
    Thevis M; Wilkens F; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2006; 20(22):3393-402. PubMed ID: 17051614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids.
    Georgakopoulos CG; Vonaparti A; Stamou M; Kiousi P; Lyris E; Angelis YS; Tsoupras G; Wuest B; Nielen MW; Panderi I; Koupparis M
    Rapid Commun Mass Spectrom; 2007; 21(15):2439-46. PubMed ID: 17610244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503.
    Thevis M; Beuck S; Thomas A; Kortner B; Kohler M; Rodchenkov G; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Apr; 23(8):1139-46. PubMed ID: 19280612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
    Bredehöft M; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for two selective androgen receptor modulators using gas chromatography-mass spectrometry in doping control analysis.
    Thevis M; Kohler M; Schlörer N; Fusshöller G; Schänzer W
    Eur J Mass Spectrom (Chichester); 2008; 14(3):153-61. PubMed ID: 18708695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes.
    Beuck S; Schänzer W; Thevis M
    J Mass Spectrom; 2011 Feb; 46(2):112-30. PubMed ID: 21254313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry.
    Thevis M; Krug O; Schänzer W
    J Mass Spectrom; 2006 Mar; 41(3):332-8. PubMed ID: 16421876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS.
    Thomas A; Geyer H; Kamber M; Schänzer W; Thevis M
    J Mass Spectrom; 2008 Jul; 43(7):908-15. PubMed ID: 18563864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.